Redefining biotherapeutics and cell and gene therapies with transposon-based technologies

Stable transgene expression using plasmid-based transfection relies on recombination for integration of transgene(s) into the host cell’s genome. However, as this approach leads to random integration of the transgene it results in variability in transgene copy number and expression in the transfected cells.

With a transposon-based method a more reliable and reproducible way of integrating DNA into the host’s genome can be achieved. In this whitepaper learn about the transposon technology that can aid the streamlining of your cell line development workflows. With its simpler, faster, and consistent generation of highly producing pools, you will be able to generate representative material earlier, accelerating downstream processing development and produce adequate material for early preclinical studies.

Covering areas including:

• Introduction to transposon technology
• Transposons use in production and cell and gene therapy
• The safety improvements and potential of the technology
• Revvity's CHOSOURCE TnT Transposon technology available for license

The CHOSURCE Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.